|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
complement inhibition
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:availability
|
consistent
|
|
gptkbp:class
|
gptkb:drug
|
|
gptkbp:clinical_trial
|
ongoing
Phase 3
immunosuppressive therapy
|
|
gptkbp:contraindication
|
hypersensitivity to components
|
|
gptkbp:developed_by
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
none required
solution for infusion
|
|
gptkbp:duration
|
ongoing
|
|
gptkbp:education
|
important
|
|
gptkbp:effective_date
|
December 2019
|
|
gptkbp:feedback
|
generally favorable
|
|
gptkbp:formulation
|
sterile liquid
|
|
gptkbp:frequency
|
every 8 weeks
|
|
gptkbp:healthcare
|
gptkb:battle
improving
necessary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ultomiris
|
|
gptkbp:indication
|
chronic kidney disease
|
|
gptkbp:ingredients
|
gptkb:ravulizumab
|
|
gptkbp:interacts_with
|
none significant known
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
demonstrated
|
|
gptkbp:is_monitored_by
|
complement levels
|
|
gptkbp:is_used_for
|
treatment of paroxysmal nocturnal hemoglobinuria
treatment of atypical hemolytic uremic syndrome
|
|
gptkbp:lifespan
|
approximately 15 days
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
global
|
|
gptkbp:marketed_as
|
gptkb:Ultomiris
|
|
gptkbp:pharmacokinetics
|
linear
complement inhibition
|
|
gptkbp:population
|
adults and children over 1 year
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
included
followed
|
|
gptkbp:receives_funding_from
|
gptkb:stock_market_index
|
|
gptkbp:regulatory_compliance
|
approved
|
|
gptkbp:research
|
published
|
|
gptkbp:research_areas
|
hematology
|
|
gptkbp:research_focus
|
complement system
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
injection site reactions
serious infections
|
|
gptkbp:social_structure
|
Ig G1 monoclonal antibody
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:supply_chain
|
managed
|
|
gptkbp:treatment
|
positive
|
|
gptkbp:type_of_care
|
monitored
|
|
gptkbp:type_of_insurance
|
varies
|
|
gptkbp:website
|
vein
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
4
|